PMC10079944_01
(A) Baseline PET-CT showed nodular thickening of the left parietal pleura, lung lesion in the left upper segment, and loculated pleural effusion. (B) PET-CT after SBRT revealed an increase in size and 18-FDG uptake. (C) PET-CT after 34 months of afatinib with complete response.
fonc-13-1108124-g001.jpg
PMC10079944_01_fonc-13-1108124-g001.jpg
f1
A secondary lesion was identified in the apicoposterior segment, also associated with an increased uptake (SUVmax 5.2) ( Figure 1A ). In July 2019, the patient experienced an oligoprogression within the radiation field, visualizing an enlargement and increased uptake in the follow-up PET/CT ( Figure 1B ). Figure 1C ). From August 2019 to January 2021, the patient continued afatinib until the 34th cycle maintaining CR.
(A) First ultrasound at 10.5 weeks of gestation without alterations. (B, C) Normal structural ultrasound at 15.4 weeks of gestation (according to the last menstrual period). Average fetometry of 15.5 weeks for a weight of 124 g.
fonc-13-1108124-g002.jpg
PMC10079944_01_fonc-13-1108124-g002.jpg
f2
The initial evaluation with a pelvic ultrasound reported no morphological alterations in the baby ( Figures 2A-C ).
Timeline of clinical events from diagnosis to last follow-up appointment.
fonc-13-1108124-g003.jpg
PMC10079944_01_fonc-13-1108124-g003.jpg
f3